Effects of ticagrelor and aspirin on cardiac function recovery and inflammatory response in patients with STEMI after PCI

Gai Yanhong; Luan Xiaodong; Xu Dan; Wang Ping

doi:10.3969/j.issn.1674-4055.2017.09.20

Abstract：Objective To explore the effects of ticagrelor and aspirin on cardiac function recovery and inflammatory response in patients with acute ST-segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). Methods 60 STEMI inpatients were enrolled from February 2014 to February 2016 and were divided into observation group and control group. The control group was treated with aspirin combined with clopidogrel. The observation group was treated with aspirin and ticagrelor. Cardiac function indexes and the level of inflammatory response indicators before and after treatment were compared between two groups, including left ventricular end - systolic volume index (LVESVI), left ventricular end - diastolic volume index (LVEDVI), left ventricular end-diastolic diameter (LVEDD) left ventricular ejection fraction (LVEF), serum interleukin-6 (IL-6), serum interleukin-8 (IL-8), tumor necrosis factor (TNF-α), high-sensitivity C-reactive protein (hs-CRP). The cardiovascular events and adverse events were recorded in both groups. Results Before treatment, there was no significant difference in cardiac function between two groups (P>0.05). After treatment, the Pro-BNP, LVEDD and E/A were significantly decreased, and those in the observation group was significantly lower than the control group. The LVEF in the two groups were significantly increased, and that in the observation group were significantly higher than the control group (P<0.05). There was no significant difference in the level of hs-CRP, TNF-α, IL-6 and IL-8 between the two groups before treatment (P>0.05). After treatment, the levels of hs-CRP, TNF-α, IL-6 and IL-8 in the two groups were significantly lower (P<0.05), and the levels of hs-CRP, TNF-α, IL -6 and IL-8 in the control group were significantly higher than those in the observation group (P<0.05). The incidence of cardiovascular events in the observation group was significantly lower than that in the control group (10% vs. 70%, P<0.05). The incidence of adverse reactions was in the observation group (16.13%) was lower than that in the control group (19.35%, P>0.05).Conclusion Ticagrelor combined with aspirin in the treatment of STEMI patients after PCI can effectively promote the recovery of cardiac function in patients with improved patients with inflammatory response, reduce the incidence of cardiovascular adverse events in patients with less adverse reactions.